The effect of SGLT2 inhibitor tofogliflozin on glycemic daily variation by blood glucose using CGMs in patient with type 2 diabetes.
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2016
At a glance
- Drugs Tofogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 29 Dec 2016 New trial record